Loading Events

« All Events

  • This event has passed.

Webinar IPFsym™, a platform to support the development of effective treatments for IPF patients

February 18, 2021 @ 8:00 am - 9:00 am

IPFsym™, a platform to support the development of effective treatments for IPF patients

Patients with idiopathic pulmonary fibrosis (IPF) have a low survival prognosis and limited treatment options. Underlying its clinical presentation is a complex pathophysiology.

A substantial effort is being applied across the pharmaceutical and biotechnology industries to develop treatments for IPF, but the complexity of the mechanistic pathophysiology is making it challenging.

Join DILIsym Services Chief Scientific Officer, Scott Q Siler, who will describe the features and use of IPFsym v1A to support the development of effective treatments for IPF patients.

DILIsym Services has developed a QSP model, IPFsym, designed to help develop treatments for IPF patients. IPFsym v1A can be used to evaluate how treatments can impact pulmonary fibrosis, inflammation, and respiration. In addition to including a substantial, diverse simulated population (SimPops), the current standards of care as applied to the SimPops are also included in IPFsym. Common clinical outputs like forced vital capacity (FVC) are linked to the underlying IPF pathophysiology, enabling the prediction of IPF patients’ efficacy.

Register Here

Details

Date:
February 18, 2021
Time:
8:00 am - 9:00 am
Website:
https://attendee.gotowebinar.com/register/1106591795499127309?source=Website

In Case You Missed A Recent Webinar or Product Video:

What’s new in MonolixSuite 2021

ADMET Predictor® 10.3 (APX.3): Flagship machine learning platform for ADMET modeling